<DOC>
	<DOCNO>NCT01753570</DOCNO>
	<brief_summary>This study evaluate efficacy safety MP-424 IFN beta RBV patient genotype 1/2 hepatitis C , treatment-naïve receive treatment .</brief_summary>
	<brief_title>Efficacy Safety MP-424 , Interferon Beta ( IFN Beta ) , Ribavirin ( RBV ) Treatment-Naïve Having Received Interferon Based Therapy With Chronic Hepatitis C ( CHC )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Genotype 1 2 , chronic hepatitis C , depression ( include past ) treatmentnaïve patient ever previous treatment Able willing follow contraception requirement Cirrhosis liver hepatic failure Hepatitis B surface antigenpositive HIV antibodiespositive History , concurrent hepatocellular carcinoma History , concurrent serious depression , schizophrenia , ; suicide attempt past Pregnant , lactating , suspect pregnant patient , male patient whose female partner pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Feron</keyword>
</DOC>